IDEAYA Biosciences, Inc. $IDYA Shares Acquired by Fisher Asset Management LLC

Fisher Asset Management LLC lifted its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 3.2% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 889,633 shares of the company’s stock after purchasing an additional 27,425 shares during the quarter. Fisher Asset Management LLC’s holdings in IDEAYA Biosciences were worth $30,755,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in IDYA. Baker BROS. Advisors LP lifted its stake in shares of IDEAYA Biosciences by 54.6% during the third quarter. Baker BROS. Advisors LP now owns 3,275,444 shares of the company’s stock worth $89,125,000 after buying an additional 1,156,716 shares during the period. Millennium Management LLC lifted its stake in shares of IDEAYA Biosciences by 345.2% during the first quarter. Millennium Management LLC now owns 547,637 shares of the company’s stock worth $8,970,000 after buying an additional 424,625 shares during the period. Balyasny Asset Management L.P. lifted its stake in shares of IDEAYA Biosciences by 1,619.5% during the third quarter. Balyasny Asset Management L.P. now owns 380,311 shares of the company’s stock worth $10,348,000 after buying an additional 358,194 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of IDEAYA Biosciences by 191.2% during the third quarter. Dimensional Fund Advisors LP now owns 497,048 shares of the company’s stock worth $13,525,000 after buying an additional 326,376 shares during the period. Finally, Fiera Capital Corp lifted its stake in shares of IDEAYA Biosciences by 20.0% during the third quarter. Fiera Capital Corp now owns 1,837,967 shares of the company’s stock worth $50,011,000 after buying an additional 305,698 shares during the period. 98.29% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Jeffrey Stein acquired 50,000 shares of the business’s stock in a transaction on Monday, March 2nd. The stock was bought at an average price of $32.96 per share, with a total value of $1,648,000.00. Following the completion of the acquisition, the director owned 54,281 shares of the company’s stock, valued at approximately $1,789,101.76. This represents a 1,167.95% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 4.70% of the company’s stock.

IDEAYA Biosciences Stock Performance

IDYA opened at $29.35 on Wednesday. IDEAYA Biosciences, Inc. has a fifty-two week low of $18.77 and a fifty-two week high of $39.28. The company has a fifty day moving average of $30.80 and a two-hundred day moving average of $32.79. The stock has a market capitalization of $2.58 billion, a price-to-earnings ratio of -18.34 and a beta of -0.04.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.04). The business had revenue of $6.56 million for the quarter, compared to the consensus estimate of $5.04 million. During the same period last year, the firm earned ($0.82) earnings per share. The business’s quarterly revenue was down 39.4% compared to the same quarter last year. On average, equities research analysts forecast that IDEAYA Biosciences, Inc. will post -4.28 earnings per share for the current year.

Wall Street Analyst Weigh In

IDYA has been the subject of several research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of IDEAYA Biosciences in a research note on Friday. The Goldman Sachs Group raised their target price on shares of IDEAYA Biosciences from $31.00 to $35.00 and gave the stock a “neutral” rating in a report on Tuesday, April 14th. Wedbush raised their target price on shares of IDEAYA Biosciences from $52.00 to $58.00 and gave the stock an “outperform” rating in a report on Tuesday, April 14th. Guggenheim raised their target price on shares of IDEAYA Biosciences from $50.00 to $54.00 and gave the stock a “buy” rating in a report on Tuesday, April 14th. Finally, Mizuho reduced their target price on shares of IDEAYA Biosciences from $52.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Fifteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $50.69.

IDEAYA Biosciences Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.